144 related articles for article (PubMed ID: 12790324)
1. Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance.
Roggel F; Hocke S; Lindemann K; Sinz S; Welk A; Bosl M; Pabst M; Nusser N; Braun S; Schmitt M; Harbeck N
Recent Results Cancer Res; 2003; 162():89-100. PubMed ID: 12790324
[TBL] [Abstract][Full Text] [Related]
2. Disseminated tumor cells in bone marrow may affect prognosis of patients with gynecologic malignancies.
Banys M; Solomayer EF; Becker S; Krawczyk N; Gardanis K; Staebler A; Neubauer H; Wallwiener D; Fehm T
Int J Gynecol Cancer; 2009 Jul; 19(5):948-52. PubMed ID: 19574790
[TBL] [Abstract][Full Text] [Related]
3. Detection of disseminated tumor cells in patients with gynecological cancers.
Fehm T; Becker S; Bachmann C; Beck V; Gebauer G; Banys M; Wallwiener D; Solomayer EF
Gynecol Oncol; 2006 Dec; 103(3):942-7. PubMed ID: 16889820
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and prognostic value of disseminated tumor cells in primary endometrial, cervical and vulvar cancer patients.
Walter CB; Taran FA; Wallwiener M; Rothmund R; Kraemer B; Krawczyk N; Blassl C; Melcher C; Wallwiener D; Fehm T; Hartkopf AD
Future Oncol; 2014 Jan; 10(1):41-8. PubMed ID: 24328408
[TBL] [Abstract][Full Text] [Related]
5. DTCs in breast cancer: clinical research and practice.
Janni W; Rack B; Kasprowicz N; Scholz C; Hepp P
Recent Results Cancer Res; 2012; 195():173-8. PubMed ID: 22527504
[TBL] [Abstract][Full Text] [Related]
6. Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer.
Fehm T; Banys M; Rack B; Janni W; Marth C; Blassl C; Hartkopf A; Trope C; Kimmig R; Krawczyk N; Wallwiener D; Wimberger P; Kasimir-Bauer S
Int J Gynecol Cancer; 2013 Jun; 23(5):839-45. PubMed ID: 23694981
[TBL] [Abstract][Full Text] [Related]
7. A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocols (Review).
Kasimir-Bauer S; Oberhoff C; Schindler AE; Seeber S
Int J Oncol; 2002 May; 20(5):1027-34. PubMed ID: 11956600
[TBL] [Abstract][Full Text] [Related]
8. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
9. Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.
Thurm H; Ebel S; Kentenich C; Hemsen A; Riethdorf S; Coith C; Wallwiener D; Braun S; Oberhoff C; Jänicke F; Pantel K
Clin Cancer Res; 2003 Jul; 9(7):2598-604. PubMed ID: 12855636
[TBL] [Abstract][Full Text] [Related]
10. Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization.
Riethdorf S; Pantel K
Pathobiology; 2008; 75(2):140-8. PubMed ID: 18544969
[TBL] [Abstract][Full Text] [Related]
11. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer.
Diel IJ; Cote RJ
Cancer Treat Rev; 2000 Feb; 26(1):53-65. PubMed ID: 10660491
[TBL] [Abstract][Full Text] [Related]
13. [Metastatic mechanisms of uterine malignancies and therapeutic consequences].
Lax SF; Tamussino KF; Lang PF
Pathologe; 2016 Nov; 37(6):549-556. PubMed ID: 27757531
[TBL] [Abstract][Full Text] [Related]
14. Triple simultaneous primary invasive gynecological malignancies: a case report.
Takatori E; Shoji T; Miura Y; Takeuchi S; Uesugi N; Sugiyama T
J Obstet Gynaecol Res; 2014 Feb; 40(2):627-31. PubMed ID: 24147606
[TBL] [Abstract][Full Text] [Related]
15. [Gynecological cancers and pregnancy: the point of view of the oncology gynecologist].
Morice P; Camatte S; Pautier P; Castaigne V; Germann N; Pomel C; Haie-Meder C; Lhommé C; Duvillard P; Dargent D; Castaigne D
Bull Cancer; 2002 Sep; 89(9):765-71. PubMed ID: 12368128
[TBL] [Abstract][Full Text] [Related]
16. Methods, safety, and early clinical outcomes of dose escalation using simultaneous integrated and sequential boosts in patients with locally advanced gynecologic malignancies.
Boyle J; Craciunescu O; Steffey B; Cai J; Chino J
Gynecol Oncol; 2014 Nov; 135(2):239-43. PubMed ID: 25192879
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer.
Solomayer EF; Diel IJ; Wallwiener D; Bode S; Meyberg G; Sillem M; Gollan C; Kramer MD; Krainick U; Bastert G
Br J Cancer; 1997; 76(6):812-8. PubMed ID: 9310251
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells.
Tachtsidis A; McInnes LM; Jacobsen N; Thompson EW; Saunders CM
Clin Exp Metastasis; 2016 Aug; 33(6):521-50. PubMed ID: 27189371
[TBL] [Abstract][Full Text] [Related]
19. Detection of micrometastatic disease in bone marrow: is it ready for prime time?
Janni W; Rack B; Lindemann K; Harbeck N
Oncologist; 2005 Aug; 10(7):480-92. PubMed ID: 16079315
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis and clinical significance of disseminated tumor cells in bone marrow].
Braun S; Pantel K
Dtsch Med Wochenschr; 2000 Oct; 125(41):1237-9. PubMed ID: 11076263
[No Abstract] [Full Text] [Related]
[Next] [New Search]
